Gilead Secures FDA Approval for Bixlenvo, First Single‑Tablet HIV Regimen for Suppressed Adults

The U.S. Food and Drug Administration has approved Bixlenvo, a once-daily HIV tablet from GILD, the company announced Thursday . The pill combines bictegravir, the backbone of Gilead's blockbuster Biktarvy, with lenacapavir, the first-in-class capsid inhibitor that has become the centerpiece of the company's long-term HIV strategy .

What makes the clearance notable is its scope rather than its size. Bixlenvo is the first single-tablet regimen available to adults whose virus is already suppressed but who cannot use existing one-pill options, typically because of drug resistance from older therapies, side effects, or interactions with other medicines. Gilead told CNBC that group accounts for an estimated 5% or more of people living with HIV in the United States . Dr. Jared Baeten, who heads Gilead's clinical development and virology therapeutic area, was explicit that the drug "does not aim to replace Biktarvy" and instead widens the menu of options built around lenacapavir, which spans daily pills, weekly orals and long-acting injectables .

The approval rests on two Phase 3 trials in adults already virologically suppressed. The first, ARTISTRY-1, enrolled patients with long treatment histories and resistance, a median age of 60, and daily pill counts ranging from two to 11 before the switch. Across both studies the drug held viral suppression at rates comparable to patients' prior regimens at 48 weeks with no new safety signals, and the side effects reported in at least 2% of participants were headache, nausea and diarrhea . Gilead set the list price before discounts or rebates at $4,595 for a 30-day supply, which the company says is in line with other daily single-tablet HIV treatments .

For investors the read is incremental rather than transformative: this is a defensive, franchise-extending launch into a resistant subpopulation, not a challenge to Biktarvy's base. Gilead shares traded around $145.31, down 2.4% on the session, against an analyst consensus target band of $123.00 to $180.00 with a $157.41 average across 27 covering analysts. Sentiment on the name has been steadily positive, with SentiSense reading news and social polarity at +0.29 over the past 30 days. The near-term signposts to watch are payer formulary decisions, early prescription mix between Bixlenvo and Biktarvy, and whether the lenacapavir platform's weekly and injectable formats reach approval on the timeline Gilead has laid out.

Related Stocks

• GILD